Feb 12 (Reuters) - BridgeBio Pharma said its experimental therapy boosted growth rates in children with a rare genetic ...

BridgeBio is hoping infigratinib will get another shot at approval after the medicine hit the key goals of a phase 3 study in ...

BridgeBio Pharma’s experimental drug for the most common cause of dwarfism accelerated children’s growth in a pivotal ...

Infigratinib topped “even the most optimistic expectations” for efficacy and safety in the late-stage PROPEL 3 study in ...

BridgeBio Pharma (BBIO) stock jumps as a Phase 3 trial for the company's achondroplasia therapy succeeds. Read more here.

Shares in BridgeBio were ticking up today after it revealed data from its phase 3 trial of infigratinib in achondroplasia, ...

Add Yahoo as a preferred source to see more of our stories on Google. Mackenzie Trush has Spondyloepimetaphyseal dysplasia (SEMD), a rare form of dwarfism with less than 100 known cases. Trush is 36 ...

The latest in a string of clinical wins, the late-stage data gives the company strong footing to compete with BioMarin's top seller.

Llinos Edwards was born with genetic dwarfism achondroplasia and stood at just 4ft and 3in when she stopped growing aged 14 FOR five long years, Llinos Edwards endured an agonising reality. The ...

Cierra Moore's daughter Lakelynn was diagnosed at birth with rhizomelic chondrodysplasia punctata type 1, which is a rare and ...

The medical term for dwarfism is restricted growth. The condition is typically characterized by a short stature and various other symptoms, depending on the cause of the condition. Dwarfism is ...

Feb 12 (Reuters) - BridgeBio Pharma said on Thursday its experimental therapy boosted growth rates in children with a rare genetic disorder that causes dwarfism, according to results from a late-stage ...